Lv3
378 积分 2024-07-16 加入
The RAD52 double-ring remodels replication forks restricting fork reversal
3天前
已完结
Correction to “Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor”
9天前
已完结
Unlocking the power of imidazoquinolines: recent advances in anticancer and immunotherapeutic strategies
9天前
已完结
Discovery of M5049: A Novel Selective Toll-Like Receptor 7/8 Inhibitor for Treatment of Autoimmunity
9天前
已完结
Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 8
9天前
已完结
Identification of 2-Pyridinylindole-Based Dual Antagonists of Toll-like Receptors 7 and 8 (TLR7/8)
9天前
已完结
Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapy
9天前
已完结
A novel Toll-like receptor 7/8–specific antagonist E6742 ameliorates clinically relevant disease parameters in murine models of lupus
9天前
已完结
Discovery of the TLR7/8 Antagonist MHV370 for Treatment of Systemic Autoimmune Diseases
9天前
已完结
Preclinical Evidence for the Glucocorticoid-Sparing Potential of a Dual Toll-Like Receptor 7/8 Inhibitor in Autoimmune Diseases
9天前
已完结
皖公网安备34019202002308
